Volume 17, Number 9—September 2011
Research
Estimating Effect of Antiviral Drug Use during Pandemic (H1N1) 2009 Outbreak, United States
Table 3
Literature review of effectiveness of neuraminidase inhibitors in preventing influenza-related hospitalizations*
Drug | Study type | Population | Reduction in hospitalization point estimate (95% CI) | Reference |
---|---|---|---|---|
Zanamivir | Randomized, double-blind, placebo-controlled trial | 455 patients residing in Australia, New Zealand, and South Africa age >12 y with influenza-like symptoms of <36 hours’ duration | NA | (14) |
Oseltamivir | Open-label, multicenter international study | 1,426 patients (age range 12–70 y) seeking treatment <48 h after onset of influenza symptoms | NA | (15) |
Oseltamivir | Retrospective cohort analysis | The oseltamivir and untreated control groups each included 36,751 eligible patients | 22%; HR 0.78 (0.67–0.91) | (8); claims data |
Oseltamivir | Retrospective cohort study | Oseltamivir and untreated propensity matched control groups each included 45,751 eligible patients | 30% any cause; OR 0.71 (0.62–0.83) | (9); insurance claims data |
Zanamivir | Randomized, double-blind studies in 38 centers in North America and 32 centers in Europe during the 1994–95 influenza season | 417 adults with influenza-like illness of <48 hours' duration were randomly assigned to 1 of 3 treatments | NA | (16) |
Amantadine/ rimantadine | Two randomized, double-blind, placebo-controlled trials | ≈80 patients with laboratory-documented influenza A virus (H3N2) illness <2 days' duration | NA | (13) |
Oseltamivir | Combined analysis of 10 prospective, placebo controlled, double-blind trials | 3,564 persons (age range 13–97 y) with influenza-like illness enrolled in 10 placebo-controlled, double-blind trials of oseltamivir treatment | 59% any cause reduction; 50% influenza, at risk patients | (7) |
Zanamivir | Retrospective pooled analysis of data; all studies were randomized, double-blind, and placebo-controlled with 21–28 day follow-up | 2,751 patients were recruited; of these, 321 (12%) were considered high risk and 154 were randomized to receive zanamivir | NA | (17) |
Zanamivir | Randomized, double-blind, placebo-controlled trial in primary care and hospital clinics | 356 patients age >12 y were recruited within 2 d of onset of typical influenza symptoms | NA | (12) |
Zanamivir | Pooled analyses of secondary endpoints | NA | (18) | |
Oseltamivir | Randomized controlled trial | 726 healthy nonimmunized adults with febrile influenza-like illness of <36 hours’ duration | NA | (19) |
Oseltamivir | Retrospective cohort study | 9,090 patients with diabetes and influenza | 30% any cause; RR 0.70 (0.52–0.94) | (10); insurance claims data |
Oseltamivir | Retrospective cohort study | The oseltamivir and untreated control groups each included 36,751 eligible patients, 50% with a claim for oseltamivir, 50% without | 38%; RR 0.62 (0.52–0.74) | (11); insurance claims data |
Oseltamivir | Double-blind, stratified, randomized, placebo-controlled, multicenter trial | Healthy adults (age range 18–65 y) who sought treatment <36 h after onset of influenza symptoms | NA | (20) |
Oseltamivir | Randomized, double blind, placebo-controlled study | Children age 1–12 y with fever (>100°F [>38°C]) and a history of cough or coryza <48 hours’ duration | NA | (21) |
*CI, confidence interval; NA, not applicable; HR, hazard ratio; OR, odds ratio; RR, relative risk.
References
- Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, Atkins CY. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis. 2011;52(Suppl 1):S75–82. DOIPubMedGoogle Scholar
- Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009–2010 season [cited 2010 Dec 18]. http://www.cdc.gov/H1N1flu/recommendations.htm#d
- Health IMS. Data Assets, IMS Prescription Data [cited 2010 Dec 18]. http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=a4284c30aaaa0210VgnVCM100000ed152ca2RCRD&vgnextchannel=bc42650204850210VgnVCM100000ed152ca2RCRD&vgnextfmt=default
- Reed C, Angulo FJ, Swerdlow DL, Lipsitch M, Meltzer MI, Jernigan D. Estimates of the prevalence of pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15:2004–7. DOIPubMedGoogle Scholar
- Strong M, Burrows J, Stedman E, Redgrave P. Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom. Euro Surveill 2010;15:pii:19565.
- Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009—an internet-based cross-sectional survey. Euro Surveill. 2009;14:pii:19287.
- Prosser LA, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V. Effects of adverse events of the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. Arch Pediatr Adolesc Med. 2011;165:112–8. DOIPubMedGoogle Scholar
- Beigi RH, Wiringa AE, Bailey RR, Assi T-M, Lee BY. Economic value of seasonal and pandemic influenza during pregnancy. Clin Infect Dis. 2009;49:1784–92. DOIPubMedGoogle Scholar
- Fairbrother G, Cassedy A, Ortega-Sanchez IR, Szilagyi PG, Edwards KM, Molinari N-A. High costs of infleunza: direct medical costs of influenza disease in young children. Vaccine. 2010;28:4913–9. DOIPubMedGoogle Scholar
- Keren R, Zaoutis TE, Saddlemire S, Luan XQ, Coffin SE. Direct medical costs of influenza-related hospitalizations in children. Pediatrics. 2007;119:227.
- Cox FM, Cobb MM, Chua WQ, McLaughlin TP, Okamoto LJ. Cost of treating influenza in emergency department and hospital settings. Am J Manag Care. 2000;6:205–14.PubMedGoogle Scholar
Page created: June 19, 2012
Page updated: June 19, 2012
Page reviewed: June 19, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.